Compounded Semaglutide: What 16 FDA Warning Letters Objected To

On 8 June 2026 the US Food and Drug Administration issued sixteen warning letters on the same day, all to companies selling compounded semaglutide — fifteen of them compounded tirzepatide as well, and two liraglutide. It is the largest single-day action against this market so far, and it went almost unreported.

What makes it worth reading is not the number. It is that the letters do not allege the drugs were contaminated, underdosed or dangerous. They allege that two specific things the companies said in their marketing were false or misleading — and both are phrases a careful shopper would read as reassuring.

What the FDA actually objected to

Every letter rests on the same legal footing: sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. A drug is misbranded if its labelling is false or misleading in any particular; a compounded drug is misbranded if its advertising or promotion is. Selling a misbranded drug across state lines is a prohibited act under section 301(a).

The FDA reached those conclusions by reviewing the companies' own websites in May 2026. Two families of claim recur.

1. "FDA-approved pharmacy" — a designation that does not exist

Several sites told customers their medication came from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. The letter to Maximus Health addresses this directly:

Compounding facilities, including pharmacies and outsourcing facilities, are not "FDA-approved" or "FDA-licensed" entities. The FD&C Act does not establish an "FDA-approved" or "FDA-licensed" designation for pharmacies or outsourcing facilities.

This is the single most useful thing in the whole action, because the phrase is everywhere. There is no such thing as an FDA-approved pharmacy. The agency approves drugs and licenses biologics. It registers outsourcing facilities and inspects them, and states license pharmacies — but no part of that produces an "FDA-approved pharmacy", and a company claiming one is describing something that cannot exist.

The letter to HydraMed cites the same phrase. The letter to Eden cites a variant that manages to be wrong twice over — "FDA-licensed 503(a) outsourcing facilities" — since 503A concerns compounding pharmacies and 503B concerns outsourcing facilities, and neither is licensed by the FDA.

2. Borrowing the brand's evidence

The second family is subtler, and it is the one most likely to have persuaded a real buyer. The FDA quotes claims including:

• "Clinically studied ingredients" and "Clinically studied to help patients…" (Maximus)
• "Proven to lose weight effectively" (Maximus)
• "Same active ingredient as Ozempic®" and "Same active ingredient as Wegovy and Ozempic" (Thrivelab)
• "clinically proven to work" (Thrivelab)

Read literally, "same active ingredient as Ozempic" is true. Compounded semaglutide is semaglutide. That is the entire argument for buying it, and it is why the claim works.

The FDA's position is that saying it in this context misbrands the product, because it transfers the brand's evidence to something that never earned it:

Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.

The distinction is real and easy to lose. STEP 1 and SURMOUNT-1 tested a specific manufactured product at a specific purity, in a specific device, at doses established by that product's own trials. A compounded preparation containing the same molecule inherits none of that testing. It may be excellent. Nothing has established that it is.

Who received a letter

All sixteen are dated 8 June 2026. Every one concerns compounded semaglutide; all but Thrivelab also concern compounded tirzepatide, and Momentum Health adds liraglutide.

A warning letter is an allegation, not a finding of guilt. Each recipient had fifteen business days to respond, and a company that corrects the wording has addressed the violation the letter describes. Several of these sites read differently now than they did in May.

The wider record: 32 letters since September 2025

The June action is not isolated. Searching the FDA's warning-letter database for the GLP-1 molecules involved in compounding and grey-market sale returns thirty-two distinct letters since September 2025:

Three legally distinct groups sit inside that total, and the difference matters more than the count.

The retatrutide letters allege the sale of an unapproved new drug. Retatrutide has no approved application in the United States at all, so offering it is a violation on its face — see can you buy retatrutide.

The June letters allege misbranding only. Compounding under sections 503A and 503B is lawful when its conditions are met; what the FDA objected to was how the products were described. That is a narrower charge, and it is why the action reached companies most people would consider mainstream rather than grey-market.

The manufacturer letters are a third thing entirely. On the same day the FDA wrote to the four retatrutide sellers, it also wrote to the chief executives of Eli Lilly and Novo Nordisk — the companies that make the approved products — over direct-to-consumer advertising and the presentation of risk information. Novo received a second letter on 5 March 2026. Worth knowing before treating "warning letter" as shorthand for a disreputable operator: the two largest manufacturers in this market have three between them.

What this does and does not tell you

It would be easy to read sixteen letters as proof that compounded GLP-1s are dangerous. That is not what these say, and overstating them helps nobody.

What the letters establish: sixteen companies described their products in ways the FDA considers false or misleading, and the two recurring descriptions are ones a reasonable person would find reassuring.

What they do not establish: anything about what was in the vials. No testing is described. No contamination, potency failure or patient harm is alleged in these sixteen letters.

The gap between those two statements is the honest position, and it is uncomfortable: the marketing was found wanting and the product was not examined. If you are weighing a compounded product, the letters tell you the seller's claims cannot be taken at face value. They do not tell you the medication is bad.

What to check if you are buying compounded

• Treat "FDA-approved pharmacy" as a red flag rather than a credential. It is not a thing. A site using it is either careless with regulatory language or counting on you not knowing — and neither is a good sign in a company shipping you an injectable.
• Separate the molecule from the product. "Same active ingredient as Ozempic" is true and tells you nothing about the preparation, the sterility, or the dose accuracy of what arrives.
• Ask which facility compounds it, and under 503A or 503B. Outsourcing facilities register with the FDA and are inspected against CGMP; 503A pharmacies are state-licensed and compound per prescription. Both are legitimate; they are not the same, and a company that cannot tell you which applies is telling you something.
• Check the warning-letter database yourself. It is public and searchable by company name, and it takes a minute.
• Compare against the approved route first. Manufacturer self-pay pricing has fallen sharply — see Zepbound's savings card, Wegovy's, and our cost index. For several people the approved product is now cheaper than they assume.

Related reading: compounded semaglutide versus Wegovy, buying compounded GLP-1s online, and how to choose a telehealth provider.

Correction, 8 August 2026: this article first published counting fifteen letters on 8 June and twenty-five in the wider record. Extending our FDA monitoring to warning letters the same day surfaced a sixteenth June letter (Momentum Health 360), four earlier ones, and letters to Eli Lilly and Novo Nordisk over advertising. The figures above are the corrected ones.

This article is educational and is not medical or legal advice. It reports the contents of public FDA warning letters read on 8 August 2026; those letters describe alleged violations that recipients have the opportunity to address. Discuss any medication decision with your prescriber.